plod2 monoclonal antibody  (Proteintech)

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Expressing

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: The primer sequences were used in qRT-PCR

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques:

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: PLOD2, CD44, and CD133 mRNA expression levels and protein in 8 pairs of human LSCC tissues and matched adjacent nontumor tissues. a Relative PLOD2, CD44, and CD133 RNA expression in 8 pairs of LSCC tumor tissues (T) and matched adjacent nontumor tissues (N). b Relative PLOD2, CD44, and CD133 protein expression in human LSCC tumor tissues and matched adjacent nontumor tissues. α-Tubulin was measured as the loading control

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Expressing, RNA Expression

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: IHC analysis of the expression levels of PLOD2, CD44, and CD133 in laryngeal tumor samples with different clinical stages (1, 2, 3 and 4), T stages (T1 & T2, T3 & T4), N stages (N0, N1-N3), and M stages (M0, M1). The expression of PLOD2, CD44 and CD133 was increased in the advanced-stage LSCC tumor tissues. Magnification: × 200

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Expressing

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: Correlation between PLOD2 expression and clinicopathological characteristics of laryngeal cancer patients

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Expressing

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: Univariate and multivariate analysis of factors associated with overall survival in 114 laryngeal cancer patients

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques:

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: OS curves based on different PLOD2 expression levels. a Kaplan-Meier survival curves for LSCC patients with high PLOD2, CD44 and CD133 expression (red line) versus low PLOD2, CD44 and CD133 expression (blue line). b Kaplan-Meier survival curves for LSCC patients with high PLOD2 and CD44/CD133 expression (red line) versus low PLOD2 and CD44/CD133 expression (blue line)

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Expressing

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: Manifestations of PLOD2 maintaining CSC characteristics. a Hep-2 and FaDu cell lines were engineered for the overexpression or silencing of PLOD2. b The SP was analyzed in the different cell lines by multiparametric flow cytometry. c Hep-2 and FaDu cell spheres cultured in medium were photographed; representative images are shown. Scale bar = 50 μm. d The mRNA expression levels of genes representing CSC markers were upregulated. e The protein expression levels of genes representing CSC markers were upregulated. * P < 0.05

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Over Expression, Flow Cytometry, Cell Culture, Expressing

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: PLOD2 could promote drug resistance in laryngeal cancer cells. a Apoptotic scatter plot; Annexin V-FITC and PI staining of the indicated cells treated with DDP (50 μM) for 48 h. b IC50 of DDP in the indicated cells. Each bar represents the mean ± SD of five independent experiments. * P < 0.05. FITC, fluorescein isothiocyanate; PI, propidium iodide

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Staining

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: PLOD2 overexpression contributes to drug resistance in Hep-2 cells in vivo. a Representative photographs of tumors isolated from the experimental mice (with/without DDP treatment). b Cleaved caspase 3 was significantly decreased in PLOD2-overexpressing Hep-2 cells. c Tumor volumes of the experimental mice during the treatment period. Each bar represents the mean ± SD of five independent experiments

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Over Expression, In Vivo, Isolation

Journal: BMC Cancer

Article Title: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

doi: 10.1186/s12885-019-6029-y

Figure Lengend Snippet: PLOD2 overexpression could activate the Wnt signaling pathway. a The mRNA levels of downstream genes of the Wnt signaling pathway(c-myc, CD44, Snail, TCF4, and MMP-2) were upregulated by PLOD2. β-Actin was used as an internal control. b Dual luciferase assay showing the effect on TOP/FOP reporter activity in LSCC cells following the overexpression and silencing of PLOD2. c Immunoblot assay of c-myc, β-catenin, MDR-1, and MRP protein levels in LSCC cells transfected with PLOD2 and controls. GAPDH was used as an internal control

Article Snippet: The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Techniques: Over Expression, Luciferase, Activity Assay, Western Blot, Transfection

Journal: bioRxiv

Article Title: Inflammation promotes tumor aggression by stimulating stromal cell-dependent collagen crosslinking and stromal stiffening

doi: 10.1101/2020.02.13.948141

Figure Lengend Snippet: ( a-b ) Kaplan-Meier plots showing overall survival for patients based on levels of LOX expression in epithelial cells (low n = 28, high n = 36) ( a ) or stromal cells (low n = 23, high n = 24) ( b ). The median level of expression was defined as the cutoff for low and high expression. ( c-d ) Kaplan-Meier plots showing overall survival for patients based on levels PLOD2 expression in epithelial cells (low n = 28, high n = 29) ( c ) or stromal cells (low n = 23, high n = 24) ( d ). The median level of expression was defined as the cutoff for low and high expression. ( e ) Schematic depicting the experimental timeline used to inhibit lysyl hydroxylase 2 in PyMT mice. ( f ) Representative polarized light images with brightfield insets of picrosirius red stained tumor tissue from PBS vehicle treated control (n = 8) and minoxidil treated (n = 7) PyMT mice. Scale bar is 100um. ( g ) Quantification of fibrillar collagen by picrosirius red staining by percent area per field of view. The mean was calculated and plotted for each animal ± SEM. ( h ) Histogram showing the distribution of the top 10% of elastic modulus measurements by AFM microindentation in PyMT control and Lox OX tumors. Statistical analysis was performed using Mann-Whitney U test (****p < 0.0001). ( i ) Scatter plot quantifying the area of lung sections occupied by metastases from vehicle treated (n = 9) and minoxidil treated (n = 8) mice at 13 weeks of age via H&E staining and assessing 4 layers (5 micron section; 5 sections per layer; 50-100 microns steps). Statistical analysis was performed using a two-tailed unpaired t-test (*p < 0.05). ( j ) Representative phase contrast images of sections from tissue microarrays (TMAs) of human breast cancers representing incident breast cancer cases collected and arrayed as 1-mm cores from each tumor. Sections were stained with Hematoxylin and Eosin (H&E; top) and lysyl hydroxylase two (LH2; bottom) via immunohistochemistry. ( k ) Bar graphs showing clinical correlation between lysyl hydroxylase two (LH2) score as a function of tumor grade ( see Table 1 for number of patients ). LH2 IHC staining was assessed with the semi-quantitative stromal specific H-score from 0 to 300. The lowest tertile of LH2 H-scores was defined as H-scores between 0 and less or equal to 120, the intermediate H-score to above 120 and equal or less than 230, and the highest stromal LH2 score as above 230. For tumor grade and LH2 H score, statistical analysis was performed using a linear-by-linear association (*** P<0.0001 ). ( l ) Kaplan-Meier curves indicating cumulative breast cancer specific survival (BCSS) based on stromal LH2 H score assessed in breast cancer patients up to 10 years after diagnosis (LH2 low n = 175, intermediate n = 188, high n = 146). ( m ) BCSS curves by stromal LH2 H score including only axillary lymph node negative patients (LH2 low n = 116, intermediate n = 116, high n = 90). ( n ) BCSS curves by stromal LH2 H score including only axillary lymph node positive patients (LH2 low n = 44, intermediate n =63, high n = 54). For Kaplan-Meier curves, statistical analyses were performed by LogRank test.

Article Snippet: A primary mouse monoclonal Lysyl Hydroxylase 2 (LH2) antibody (Origene; Cat# TA803224, dilution 1:150) was used for the immunohistochemical staining.

Techniques: Expressing, Staining, MANN-WHITNEY, Two Tailed Test, Immunohistochemistry